$6.76
+0.18 (+2.81%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where ALGS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
15 interventional · 2 with posted results
Held by 6 tracked-famous managers (MARSHALL WACE, LLP, HHLR ADVISORS, LTD., D. E. Shaw & Co., Inc., JANE STREET GROUP, LLC, Verition Fund Management LLC, +1 more) · FINRA short interest 6.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)NCT06963710HBeAg positive: HBV DNA <Lower Limit of Quantification [LLOQ] (10 IU/mL, target detected or target not detected)Randomized · Quadruple-masked · Treatment | Phase 2 | Active, not recruiting | Drug: ALG-000184, TDF | Chronic Hepatitis B Infection | 200 | Mar 2027 | ≤ 224 d | 2026-08-18 |
| Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal FunctionNCT07342881Area under the concentration time curve [AUC]Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Pevifoscorvir Sodium (ALG-000184) | Chronic Hepatitis B Infection | 30 | 2026-06-15 | — | 2026-02-27 |
| Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic FunctionNCT07342868Area under the concentration time curve [AUC]Non-randomized · Open-label · Treatment | Phase 1 | Recruiting | Drug: Pevifoscorvir Sodium (ALG-000184) | Chronic Hepaititis B Infections | 16 | 2026-04-20 | — | 2026-02-04 |
| A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy VolunteersNCT06672900Area under the concentration time curve [AUC]Non-randomized · Open-label · Other | Phase 1 | Active, not recruiting | Drug: Carbamazepine, Itraconazole (Sporanox), ALG-000184 | Healthy Volunteer | 24 | 2025-07-07 | — | 2025-02-03 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal FunctionNCT06698549results2026-07-09Area Under the Concentration Time Curve [AUC]Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: ALG-097558 | COVID 19 | 12 | 2025-07-23actual | — | 2026-07-09 |
| A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic FunctionNCT06568861results2026-08-05Area Under the Concentration Time Curve [AUC]Non-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: ALG-097558 | COVID-19 | 16 | 2025-07-16actual | — | 2026-08-05 |
| A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB SubjectsNCT04536337Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: ALG-000184, Placebo, Entecavir | Chronic Hepatitis B | 165 | 2025-06-16actual | — | 2025-11-21 |
| A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 FormulationsNCT06959888AUC0-24 of ALG-055009 in PlasmaRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: ALG-055009 | Healthy Volunteer Study | 8 | 2025-05-08actual | — | 2025-07-09 |
| ALG-055009 in Non-cirrhotic Adults With MASH (HERALD)NCT06342947Percent relative change from baseline in liver fat contentRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: ALG-055009, Placebo | NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis | 102 | 2024-08-19actual | — | 2025-02-17 |
| A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558NCT05840952Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: ALG-097558, Placebo, Midazolam, Itraconazole, Carbamazepine, ALG-097558 in solution formulation, ALG-097558 in tablet formulation | COVID-19 | 90 | 2024-04-29actual | — | 2025-04-08 |
| A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)NCT06191991Area under the concentration time curve [AUC]Non-randomized · Open-label · Other | Phase 1 | Completed | Drug: Atorvastatin, ALG-055009, Rosuvastatin | Healthy Volunteers | 14 | 2023-11-27actual | — | 2025-02-17 |
| A Study of ALG-055009 in Healthy Volunteers and Subjects With HyperlipidemiaNCT05090111Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: ALG-055009, Placebo | NASH - Nonalcoholic Steatohepatitis | 98 | 2023-06-16actual | — | 2023-09-25 |
| A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB SubjectsNCT05561530Incidence and severity of treatment emergent adverse events as assessed by DAIDS v2.1 of various doses of ALG-125755 in HV subjects and CHB subjectsRandomized · Quadruple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Single doses demonstrated an acceptable safety profile and antiviral activity at all doses evaluated. | Drug: ALG-125755, Placebo | Chronic Hepatitis B | 57 | 2023-06-15actual | — | 2024-03-15 |
| A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB SubjectsNCT05001022Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Randomized · Quadruple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: ALT flares suggestive of drug induced liver injury | Drug: ALG-020572, Placebo | Chronic Hepatitis B | 40 | 2022-07-18actual | — | 2023-04-25 |
| A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB SubjectsNCT04485663Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Randomized · Quadruple-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Lack of antiviral activity at the projected efficacious dose. | Drug: ALG-010133, Placebo | Chronic Hepatitis B | 103 | 2022-03-08actual | — | 2022-03-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19